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BAYESIAN TESTING OF MANY HYPOTHESES × MANY GENES:
A STUDY OF SLEEP APNEA
B Y S HANE T. J ENSEN , I BRAHIM E RKAN , E RNA S. A RNARDOTTIR ,
AND DYLAN S. S MALL
University of Pennsylvania, University of Pennsylvania, Landspitali University
Hospital and University of Pennsylvania
Substantial statistical research has recently been devoted to the analysis
of large-scale microarray experiments which provide a measure of the simultaneous expression of thousands of genes in a particular condition. A typical goal is the comparison of gene expression between two conditions (e.g.,
diseased vs. nondiseased) to detect genes which show differential expression.
Classical hypothesis testing procedures have been applied to this problem and
more recent work has employed sophisticated models that allow for the sharing of information across genes. However, many recent gene expression studies have an experimental design with several conditions that requires an even
more involved hypothesis testing approach. In this paper, we use a hierarchical Bayesian model to address the situation where there are many hypotheses
that must be simultaneously tested for each gene. In addition to having many
hypotheses within each gene, our analysis also addresses the more typical
multiple comparison issue of testing many genes simultaneously. We illustrate our approach with an application to a study of genes involved in obstructive sleep apnea in humans.

1. Introduction and motivation. The advent of microarray experiments for
the measure of genome-wide gene expression have had a fundamental impact on
the study of biological mechanisms and phenomena. The simultaneous measurements of gene expression across an entire genome have allowed biologists to infer regulatory networks within genomes [e.g., Segal et al. (2003)] and investigate
the genetic mechanisms underlying disease [e.g., Alizadeh et al. (2000)]. The development of models and methodology for the analysis of gene expression data
has also become increasingly prominent within the field of statistics. Sophisticated procedures have been implemented for the processing and visualization of
expression data [e.g., Dudoit, Gentleman and Quackenbush (2003), Irizarry et al.
(2006)] as well as the clustering of expression data [e.g., Medvedovic and Sivaganesan (2002), Ma et al. (2006)]. Hypothesis testing of expression data has also
been an area of active research, with considerable focus given to proper techniques
for inference in the context of large numbers of simultaneous tests across many
genes [e.g., Storey and Tibshirani (2003), Newton et al. (2004)].
Received May 2008; revised January 2009.
Key words and phrases. Bayesian hypothesis testing, FDR control, hierarchical models, multiple
comparisons.
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In this paper we consider a special case of simultaneous testing not just across
many genes but also across many hypotheses within each gene. Our consideration
of this case is motivated by our analysis of a large study of treatment for obstructive
sleep apnea (OSA) where we are comparing many genes across several states. Obstructive sleep apnea is a common sleep disorder involving frequent and disruptive
pauses in breathing during sleep [Pack (2006)]. A large study of sleep apnea involving 13 individuals was undertaken in 2005 by Landspitali University Hospital
in Iceland. The primary goal of this study was the elucidation of genes whose expression pattern was mediated by an obstructive sleep apnea treatment: continuous
positive airway pressure (CPAP). The experimental design of their study consists
of the 13 individuals with blood samples taken at the following four time points:
1.
2.
3.
4.

Pre-treatment, Before Sleep,
Pre-treatment, After Sleep (10 hours following time point 1),
Post-treatment, Before Sleep (12 weeks following time point 2),
Post-treatment, After Sleep (10 hours following time point 3).

In this paper we will use the terms state and time point interchangeably. From the
blood samples taken at each time point, cellular mRNA expression was measured
using Affymetrix microarray technology for approximately 22,000 genes. These
expression levels are used as a measure of the activity of each gene: genes that
show high expression levels in a state are considered to be activated, genes that
show low expression levels in a state are considered to be repressed. The overall
goal of our analysis will be the identification of any genes that show differential
expression within some subset of these four time points. We have specific interest
in differential expression between particular subsets of the time points, such as
genes that show differences between the before and after states of sleep, or genes
that show differences between the before and after states of the treatment. Genes
which can be found to have their mRNA expression that is mediated by the CPAP
treatment are valuable candidates for follow-up studies into refined treatments for
sleep apnea.
We will take a hypothesis testing approach to the determination of differential expression between these states. Linear models have been used extensively
for establishing differential gene expression, such as the limma package for R
[Smyth (2004)]. We prefer the use of a Bayesian hierarchical model to allow for
gene-specific differences in expression while sharing information across genes for
the estimation of several global noise parameters. Bayesian models have been recently used for hypothesis testing between two states [Newton et al. (2004)] and
we will use a similar modeling approach in our current work. However, our present
application has several complications that require new methodological development. The application in Newton et al. (2004) consisted of only two states, which
greatly simplifies the testing situation since there are only three distinct hypotheses
(μ1 = μ2 , μ1 > μ2 , μ1 < μ2 ) that could describe the expression of any particular gene. However, our application consists of four states, which greatly expands
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the number of alternative hypotheses that might underly the observed expression
values for each gene. Kendziorski et al. (2003) extend the approach of Newton
et al. (2004) to greater than two states, but under the restriction that only twosided alternatives are considered (e.g., μ1 = μ2 = μ3 vs. μ1 = μ2 = μ3 ). This
is a restrictive assumption in our context since we desire the separate identification of activated and repressed genes between subsets of states. We prefer to take
a fully flexible approach that allows for all possible one-sided alternatives which
leads to a substantially larger space of many possible hypotheses for each gene,
and we present our Bayesian hierarchical model for the testing of many hypotheses in Section 2. Yuan and Kendziorski (2006) extend the approach of Newton et
al. (2004) to also allow clustering of genes in addition to establishing differential
expression. However, Yuan and Kendziorski (2006) take an empirical Bayes approach to model estimation instead of modeling the entire posterior distribution
of all unknown parameters. Thus, these previous approaches have favored inference based on a posterior mode found via the EM algorithm [Dempster, Laird and
Rubin (1977)], whereas we prefer a full exploration of the posterior space using
Markov chain Monte Carlo techniques such as Gibbs Sampling [Geman and Geman (1984)].
However, we also must confront a more traditional multiple comparison issue:
we are not only testing many hypotheses per gene, but also testing across many
genes in our full evaluation of the effects between pre- and post-treatment sleep
apnea. In Section 2.2 we outline our approach to controlling the false positive
rate across genes by using the posterior probabilities across hypotheses estimated
within each gene. Combined together, these procedures are a principled approach
to the increasingly common hypothesis testing context where there are many hypotheses × many genes. In Section 3 our model is applied to the gene expression
data from our motivating study of sleep apnea, and in Section 4 we perform an
extensive study of the sensitivity of our inference to several model choices and
compare our results to two alternative models available as R packages: limma and
EBarrays. We examine several individuals in detail as potential outlying values
and evaluate their influence on our gene-specific inferences, as well as examining
the possibility of the correlation between individuals in the study. We conclude
with a brief discussion in Section 5.
2. Model and implementation.
2.1. Gamma–Inv-Gamma hierarchical model. Our observed data is Xgij =
expression level of gene g (g = 1, . . . , G) in state i (i = 1, . . . , 4) for individual
j (j = 1, . . . , N ). For our Iceland study, we have G = 22,283 genes measured
across N = 13 individuals. We model these gene expression values as Gamma
observations from an underlying gene- and state-specific mean:


(1)

Xgij



αi
∼ Gamma αi ,
,
μgi

i.e., E(Xgij ) = μgi .
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As mentioned by Newton et al. (2004) and Yuan and Kendziorski (2006), the
Gamma distribution is an attractive model for expression data since many popular
processing and normalization procedures lead to expression data with approximately constant coefficient of variation. The Gamma model has constant coefficient of variation for the genes in each state, but the coefficient of variation is
allowed to vary across states. Newton et al. (2001) also discuss the Gamma distribution as a model for gene expression data, though that discussion focussed on
two-channel cDNA microarrays instead of the Affymetrix microarray technology
employed in our study.
The second level of our model treats the latent means μg = (μg1 , . . . , μg4 ) for
a particular gene g in each of the four states as random variables that each follow
an inverse-Gamma distribution,
μgi ∼ Inv-Gamma(α0 , α0 · μ0 ),

(2)

but with additional constraints on the vector μg = (μg1 , . . . , μg4 ) dictated by
a latent variable Zg . Each constraint Zg represents a different hypotheses (e.g.,
μg1 = μg2 = μg3 < μg4 ) on the underlying means for gene g. We have adopted
several elements of the model and notation of Newton et al. (2004), but our
model is more complex in the sense we are modeling four states simultaneously,
which substantially increases the number of possible hypotheses for our underlying means. For four states, there are 75 possible orderings of our μ vector when
including all possible subsets of equalities:
Zg = 0

⇒

μg1 = μg2 = μg3 = μg4 ,

Zg = 1

⇒

μg1 = μg2 = μg3 < μg4 ,

Zg = 2

⇒

μg1 = μg2 = μg3 > μg4 ,

..
.
A full list of the 75 different hypotheses are given in our supplementary materials [Jensen et al. (2009)]. We use additional notation to keep track of the
different orderings Zg in order to address the extra complexity of our problem and allow for easier generalization to applications with more than four
states. Let M(Zg ) be the number of equality groups in the ordering, and let
C(Zg , m) be the set of time-points or states contained in the mth equality group
of that ordering. We then rank the equality groups in increasing order, so that
C(Zg ) = [C(Zg , 1), . . . , C(Zg , M(Zg ))], where the members of C(Zg , 1) have
lower means than members of C(Zg , 2) which have lower means than members of
C(Zg , 3), etc. Consider a few examples:
Zg = 0 :
⇒

μ1 = μ2 = μ3 = μ4
M(Zg ) = 1,

C(Zg ) = [(1, 2, 3, 4)],
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Zg = 1 :
⇒

μ1 = μ2 = μ3 < μ4
M(Zg ) = 2,

Zg = 2 :
⇒

C(Zg ) = [(1, 2, 3), (4)],

μ1 = μ2 = μ3 > μ4
M(Zg ) = 2,

C(Zg ) = [(4), (1, 2, 3)],

..
.
Finally, we have additional parameters that specify the probabilities for each mixture component: P(Zg = k) = φk for k = 0, . . . , 74. The complete-data likelihood
of our model combines our unknown parameters  = (α, μ0 , φ) and observed
data X with our latent variables μ and Z as follows:
(3)

p(X, μ, Z|) =

 4
G 




p(Xgi |μgi , ) · p(μg |Zg , ) · p(Zg |).

g=1 i=1

We use noninformative prior distributions for each unknown parameter in  =
(α, μ0 , φ):
1. φ ∼ Dirichlet(ω) where each ωk is small (ωk = 0.001 for this study).
2. αi ∼ Uniform(0, C) where C is large (C = 10,000 for this study).
3. μ0 ∼ Uniform(0, C) where C is large (C =10,000 for this study).
Our posterior inference was not sensitive to other choices of C and ωk . We can
reduce the complexity of our model estimation by integrating over the latent geneand state-specific means μ:
p(X, Z|) =
=



p(X, μ, Z|) dμ
G


p(Zg |)

g=1

 
4



p(Xgi |μgi , ) · p(μg |Zg , ) dμg ,

i=1

which results in the following collapsed likelihood distribution:
p(X, Z|) =
(4)

G


φZg · D(Zg ) ·

g=1

(α0 μ0 )α0 ·M(Zg )
[(α0 )]M(Zg )

M(Zg )
N

αiNαi 
(A(g, m))
αi −1
X
,
×
gij
N
[(αi )] j =1
(B(g, m))A(g,m)
i=1
m=1
4








where A(g, m) = α0 + N · c αc and B(g, m) = α0 μ0 + c αc j Xgcj with
c ∈ C(Zg , m). The factor D(Zg ) is a constant related to the posterior probability of the ordering itself, which is rather complicated and discussed in detail in our
supplementary materials [Jensen et al. (2009)]. Finally, we combine this collapsed
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likelihood together with our prior distributions to give us the full posterior distribution, p(, Z|X) ∝ p(X, Z|) · p(), of our unknown parameters  and latent
variables Z.
An alternative modeling approach for the multiple group problem is provided
by Gottardo et al. (2006). Their model is based on the t-distribution for the observed expression measures with mixtures of normal prior distributions for the unobserved means. However, their approach lacks the conjugacy of our model, and
thus the unknown means μ cannot be integrated out of their model. Subsequently,
the Gottardo et al. (2006) implementation is more complicated since they must estimate all the unknown means μ, whereas we can focus our estimation on a much
smaller set of parameters . We implement our collapsed model using a relatively
simple Gibbs sampling [Geman and Geman (1984)] algorithm that approximates
the full posterior distribution of our unknown parameters (, Z) by sampling iteratively from the conditional distribution of each set of parameters given the current
values of the other parameters. Details of our Gibbs sampling algorithm are given
in the supplementary materials [Jensen et al. (2009)].
2.2. Inference for gene-specific hypotheses Zg and multiple comparison issues.
The primary goal of our investigation is to infer the correct hypothesis Zg for each
gene, with extra focus on genes that are inferred to be nonnull (Zg = 0). Our Gibbs
sampling algorithm provides an estimate of the posterior distribution for each latent variable Zg , but we still need to make a decision about which hypothesis we
infer to be correct for each gene. There are several different inferential decisions
we can make based on the posterior distribution of each Zg . The first alternative is
to assign each gene to their modal hypothesis,
(5)

h̃g = arg max P(Zg = h|X).
h=0,...,74

As discussed in Bickel and Doksum [(2007), page 165] using the hypothesis with
the largest posterior probability is an optimal strategy under a 0–1 loss function.
However, using the modal hypothesis for each gene ignores potentially important information about the confidence of our inference in each gene-specific decision. Given two genes (A and B) with modal hypothesis h , we might wish to
draw a distinction between gene A with P(ZA = h |X) = 0.9 and gene B with
P(ZB = h |X) = 0.4. One popular inferential technique is to only declare genes
to have a particular hypothesis h if their posterior probability P(Zg = h |X) exceeds a pre-defined threshold k. In biological applications where tests are being
performed across many genes simultaneously, this threshold k is chosen so that the
false discovery rate (FDR) is controlled at a desired level (say, 0.05). Our Bayesian
framework allows us to use our gene-specific posterior probabilities P(Zg |X) to directly estimate the false discovery rate for any threshold k. Newton et al. (2004)
suggest the following formula for the estimated false discovery rate for a threshold
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of k:
(6)



FDR(k) =

g P(Zg

= 0|X) × I[P(Zg = 0|X) ≥ k]
.
g I[P(Zg = 0|X) ≥ k]



The term P(Zg = 0) is the probability of an error when declaring gene g to have
a nonnull hypothesis [P(Zg = 0|X) ≥ k]. Equation (6) was valid for the Newton et
al. (2004) study since they were only concerned with FDR control for ordered
comparisons between two states. However, in our current methodology, we not
only have to control our inference across many genes, but also across many different ordered hypotheses within each gene. In this more complicated situation,
equation (6) actually underestimates the error rate, since it only measures null vs.
nonnull errors without accounting for an additional potential error: a gene correctly declared to be nonnull, but the incorrect nonnull hypothesis is inferred. In
our many hypotheses × many genes situation, we suggest the following estimated
false discovery rate for a threshold of k:


(7)

FDR(k) =

g P(Zg

= hg |X) × I[P(Zg = hg |X) ≥ k]
,
g I[P(Zg = hg |X) ≥ k]



where hg = 1, . . . , 74 is the nonnull hypotheses that is chosen for gene g. A nonnull hypothesis hg is only chosen for gene g if it is the modal hypothesis and
P(Zg = hg |X) ≥ k. In these cases, P(Zg = hg |X) is the probability of an error
when declaring gene g to have a specific nonnull hypothesis hg . Given a complete
set of estimated posterior probabilities P(Zg |X), equation (7) can be calculated
along a fine grid of potential thresholds k ∈ (0, 1), and then a particular k  is chosen to control the false discovery rate at the desired level (e.g., 0.05).
3. Results. The raw Affymetrix data was processed using the GC-RMA procedure presented in Wu et al. (2004). This preliminary analysis gives us a dataset
consisting of expression levels for 22,283 genes across the 4 states in 13 individuals. We implemented our model on this dataset using the Gibbs sampler outlined
in our supplementary materials [Jensen et al. (2009)]. Multiple chains of the Gibbs
sampler were run for 20,000 iterations. A thorough examination of the parameter values from these chains suggested that the chains had converged to the true
posterior distribution after the first 5000 iterations. These initial 5000 iterations
were discarded as burn-in, and our inference is based on the remaining iterations.
We first examine our model parameters  in Section 3.1 and then focus on our
primary goal: gene-specific inference for our Z indicators in Section 3.2.
3.1. Inference for model parameters . We examine our model parameters 
by first considering the global parameters (α, μ0 ) which are shared across all
genes. In Figure 1 we present the posterior distributions of the global parameters (α1 , α2 , α3 , α4 ) from our observed data level (1) as well as the global parameters (α0 , μ0 ) from our latent variable level (2). We see in Figure 1 that there
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F IG . 1. The first set of boxplots are the posterior distributions for the global parameters
(α1 , α2 , α3 , α4 ) from our observed data level. The second set of boxplots are the posterior distributions of the global parameters (α0 , μ0 ) from our latent variable level.

is variability in each parameter which is only captured by our estimation of the
full posterior distribution, compared to previous approaches [Newton et al. (2004),
Yuan and Kendziorski (2006)] that focussed on point estimates of each parameter.
Another interesting result from Figure 1 is that the distributions of the shape parameters (α1 , α2 , α3 , α4 ) are each centered at different values, suggesting that there
are global differences in the gene expression measures between the four states of
the experiment.
The other global parameters φ = (φ0 , φ1 , . . . , φ74 ) represent the marginal probabilities of each hypothesis across the 22,283 genes in our dataset. In Figure 2
we present the posterior means of the marginal probability φk for each hypothesis k, as estimated from our Gibbs sampling output. All 75 hypotheses are represented in the left barplot in Figure 2, but only the 74 nonnull hypotheses are
present in the right barplot. The most striking feature of Figure 2 is the sparsity of the probabilities over the set of possible hypotheses. The null hypotheses (μ1 = μ2 = μ3 = μ4 ) dominates with a posterior mean φ 0 = 0.735. This is
an expected result, since the majority of genes are involved in cellular processes
that are not circadian or affected by sleep vs. wakeful state. In order to illuminate
other popular hypotheses, we removed the null hypotheses from the comparison
in the bottom plot of Figure 2. The other prominent hypotheses are hypothesis 10
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F IG . 2. Plot (a) is a barplot of the posterior mean of φk for the ten hypotheses with the largest
values of φk . Plot (b) is a barplot of the posterior mean of φk for the ten hypotheses (excluding the
null hypothesis) with the largest values of φk .

(μ1 = μ3 < μ2 = μ4 ) with φ 10 = 0.118 and hypothesis 13 (μ1 = μ3 > μ2 = μ4 )
with φ 13 = 0.078. These two hypotheses represent genes that show change between morning and evening but do not seem to show change between time point 2
and time point 3. These genes can be either circadian, affected by sleep or by
other changes that occur between the evening and morning measurements. We
will refer to these genes as circadian in our subsequent analysis. The remaining hypotheses represent genes that could be affected by treatment (i.e., either
μ1 = μ3 or μ2 = μ4 ). As seen in Figure 2, these other hypotheses have quite
low marginal posterior probabilities, with the highest probability among them being hypothesis 32 (μ1 = μ3 < μ4 < μ2 ) with φ 32 = 0.001. However, it is important to emphasize that although the marginal posterior probabilities of these
hypotheses are quite small, there are still many genes from our pool of 22,283
genes that can be inferred into these hypotheses, as we see in Section 3.2 below.
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3.2. Inferred hypotheses for each gene. The primary goal of our analysis is
to infer the correct hypothesis for each gene in our dataset, which is represented
in our model by the latent indicator variable Zg for g = 1, . . . , 22,283. Naturally,
we are especially interested in inferring the correct hypothesis for genes that do
not seem to be in the null category Zg = 0. Our Gibbs sampling implementation
gives us an estimate of the P(Zg = h|X) for each of the 75 possible hypotheses for
gene g. As described in Section 2.2, we infer a particular nonnull hypotheses h
to be correct for gene g if P(Zg = h |X) > k where the threshold k is chosen to
control the false discovery rate given in (7). Genes with P(Zg = h |X) that do not
achieve this threshold for any nonnull hypothesis are inferred to be in the null
category. It is worth noting again that this procedure is designed to control the
false discovery rate for not only the multiple comparisons across many genes but
also the multiple comparisons across many hypotheses within each gene. For our
dataset of 22,283 genes, the threshold k = 0.645 controls the FDR below a level
of 0.05. Using this threshold gives us 4083 genes (18%) that are inferred to have
nonnull hypotheses. The number of genes that were inferred to have each nonnull
hypotheses Zg = h (h = 1, . . . , 74) are given in Table 1.
From Table 1, we see that many nonnull hypotheses are inferred for at least
one gene in our dataset, despite the relatively low marginal probability of most
of these hypotheses (Section 3.1). Hypotheses 10 and 13, which are circadian
genes, are by far the most popular nonnull hypotheses (98% of nonnull genes).
However, there are several groups of genes that do not have a circadian pattern, with the most prominent being hypotheses 25 (μ4 < μ2 < μ1 = μ3 ) and 32
(μ2 > μ4 > μ1 = μ3 ). Genes with these two inferred hypotheses show identical
pre-sleep expression levels both before and after treatment (μ1 = μ3 ), but different
post-sleep expression patterns between the before and after treatment time points
(μ2 = μ4 ). The next two most popular hypotheses, 3 (μ3 < μ1 = μ2 = μ4 ) and
33 (μ3 > μ1 > μ2 = μ4 ), show the opposite trend with the same expression levels
post-sleep before and after treatment (μ2 = μ4 ), but different activity in the presleep points before and after treatment (μ3 = μ1 ). In both situations, it is possible
that the applied treatment is affecting some cellular process involving these genes.
These genes are candidates for follow-up analyses into the genetic basis of sleep
behavior, as well as more refined potential treatments of sleep apnea.
3.3. Collapsing hypotheses groups. We can further refine our search for
treatment-mediated genes by collapsing our 74 possible nonnull hypotheses into a
smaller set of hypothesis groups of particular biological interest. As an example,
we can combine hypothesis 10 and hypothesis 13 into a single hypothesis group
C1 of genes that are circadian (μ1 = μ3 = μ2 = μ4 ). Similarly, we can combine
the ten different hypotheses for which μ1 = μ2 but μ3 = μ4 into a single hypothesis group C2 of genes that may be affected by the treatment. Also of interest is
the opposite group C3 of genes that may be affected by the treatment (μ1 = μ2
but μ3 = μ4 ). These hypothesis groupings are listed in Table 2. For now, we focus
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TABLE 1
Number of inferred genes and marginal probabilities φg for each inferred hypothesis

Zg

Hypothesis

φg

Number of inferred genes

10
13
25
32
3
33
4
21
6
28
2
5
9
20
37
43
48
61
64
71
7
8
14
16
22
39
42
44
51
72

μ 1 = μ3 < μ 2 = μ4
μ 2 = μ4 < μ 1 = μ3
μ 4 < μ 2 < μ 1 = μ3
μ 2 > μ 4 > μ 1 = μ3
μ 3 < μ 1 = μ2 = μ4
μ 3 > μ 1 > μ 2 = μ4
μ 4 < μ 1 = μ2 = μ3
μ 3 < μ 1 < μ 2 = μ4
μ 2 > μ 1 = μ3 = μ4
μ 1 > μ 3 > μ 2 = μ4
μ 2 < μ 1 = μ4 = μ3
μ 1 > μ 2 = μ3 = μ4
μ 1 = μ2 < μ 3 = μ4
μ 2 < μ 4 < μ 1 = μ3
μ 4 > μ 2 > μ 1 = μ3
μ 2 < μ 1 = μ4 < μ 3
μ 4 < μ 1 = μ2 < μ 3
μ2 < μ4 < μ1 < μ3
μ3 < μ1 < μ4 < μ2
μ4 < μ2 < μ1 < μ3
μ 3 > μ 1 = μ4 = μ2
μ 4 > μ 1 = μ2 = μ3
μ 3 = μ4 < μ 2 = μ1
μ 1 < μ 3 < μ 2 = μ4
μ 3 < μ 2 < μ 1 = μ4
μ 1 < μ 2 = μ3 < μ 4
μ 2 < μ 1 = μ3 < μ 4
μ 2 < μ 3 = μ4 < μ 1
μ1 < μ2 < μ3 < μ4
μ4 < μ2 < μ3 < μ1

0.11791
0.07822
0.00099
0.00111
0.00095
0.00095
0.00095
0.00096
0.00099
0.00099
0.00095
0.00095
0.00095
0.00095
0.00095
0.00095
0.00095
0.00095
0.00095
0.00095
0.00094
0.00094
0.00094
0.00094
0.00094
0.00094
0.00094
0.00094
0.00094
0.00094

2433
1580
9
7
5
5
4
4
3
3
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1

on the results from our model which are given in the third and fourth column of
Table 2.
For any particular gene, the posterior probability of belonging to a particular
hypothesis group (e.g., C1) can be calculated directly by summing the estimated
probabilities P(Zg = h|X) over all hypotheses contained in that group. Our procedure for choosing an FDR-calibrated threshold (Section 2.2) can then be performed
on this collapsed set of hypothesis groups instead of the full set of hypotheses. For
this collapsed set of hypothesis groups, a threshold k  = 0.595 controls the FDR
below a level of 0.05, which is a slightly more liberal threshold than k = 0.645
used in our un-collapsed analysis in Section 3.2. Using this threshold, we infer
4270 genes to have nonnull hypotheses, compared to the 4083 genes inferred to be
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TABLE 2
Description of collapsed hypotheses groupings and results from our model compared to the
EBarrays software discussed in Section 4.1
Our Model
Description
Label (contained hypotheses)

EBarrays

Marginal # of inferred Marginal # of inferred
probs φ
genes
probs φ
genes

C0

Null: μ1 = μ2 = μ3 = μ4
(0)

0.735

18,013

0.752

17,374

C1

Circadian: μ1 = μ3 = μ2 = μ4
(10, 13)

0.196

4102

0.228

4636

C2

Treatment-affected A: μ1 = μ2 but
μ3 = μ4 (1, 2, 5, 6, 15, 18, 27, 30, 41, 44)

0.009

18

0.001

18

C3

Treatment-affected B: μ1 = μ2 but
μ3 = μ4 (3, 4, 7, 8, 23, 26, 35, 38, 45, 48)

0.009

29

0.002

13

nonnull in Section 3.2. The number of genes inferred into each collapsed hypotheses grouping is also given in Table 2. We see that the inferred nonnull genes are
still dominated by circadian genes, but there are quite a few genes in the C2 and
C3 groups (18 and 29 resp.) that seem to be affected by treatment.
4. Model comparison and sensitivity. We have presented a sophisticated hierarchical model to address the many hypotheses × many genes situation presented
by the current sleep apnea study. In this section we compare our analysis to results
from a related method by Yuan and Kendziorski (2006), and discuss differences
and limitations. In addition, the complexity of our approach requires us to verify the validity of several model assumptions in detail. We explore the possibility
that one or two suspicious patients have a substantial effect on our inference in
Section 4.3. In Section 4.4 we explore the potential consequences of one simplifying assumption of our model, that our gene expression measurements within each
timepoint are treated as independent replications. Finally, in Section 4.5 we evaluate the sensitivity of our model by examining the empirical effect sizes for the
inferred genes for several different hypotheses.
4.1. Comparison with the limma and EBarrays procedures. As discussed
in our introduction, there have also been several recent applications of Bayesian
hypothesis testing to gene expression data [Kendziorski et al. (2003), Newton et
al. (2004), Yuan and Kendziorski (2006)]. The EBarrays R package (version 2.2.0) implements a version of these general approaches that allows for testing
of multiple hypotheses in a similar fashion to our proposed methodology. However, the EBarrays procedure differs from our model in several important ways.
First, parameter estimation in EBarrays is performed using an EM algorithm

1092

JENSEN, ERKAN, ARNARDOTTIR AND SMALL

[Dempster, Laird and Rubin (1977)] which focuses on point estimation instead of
our favored approach of estimating the full posterior distribution of each parameter. Second, a single shape parameter α is used for all states in the observed data
level, which in our notation is equivalent to assuming α1 = α2 = α3 = α4 = α. The
estimated value of their single parameter is α̂ = 21.3, which is within the range of
our αi values. However, as we see in Figure 1, our analysis finds substantial differences in the posterior distributions of our separate αi parameters that is not modeled in EBarrays. On a more technical note, although EBarrays is capable
of handling ordered alternative hypotheses, the full set of 75 hypotheses ordered
hypotheses used by our analyses could not be fit by EBarrays (errors were produced within the EBarrays version 2.2.0 optimization routine). Instead, we used
EBarrays to fit the full set of twelve unordered hypotheses. We focus our attention on the EBarrays results for the unordered hypotheses that correspond to our
collapsed hypotheses groupings examined in Section 3.3.
Similar to our method, EBarrays produces parameter point estimates as well
as posterior probabilities for each gene × hypothesis combination. We use the
same FDR control procedure described in Section 2.2 to infer genes into each
hypothesis. In Table 2 we compare EBarrays to our analysis in terms of the
marginal probabilities φ and number of inferred genes for each hypothesis grouping. Assuringly, there are some strong similarities between our analysis and the
results produced by EBarrays, such as the correspondence between the analyses
on the marginal probability of the null hypotheses φ0 . The most striking difference between the results is that many more genes are inferred into the circadian
category (C1) by EBarrays, whereas we see slightly more genes inferred into
the treatment category C3 with our method. This small difference could be due to
a decreased resolution toward rare hypotheses caused by the EBarrays assumption of a single shape parameter α shared across all four states. We also compared
our results to a much simpler analysis based on a linear model as implemented
by the limma R package. In the standard limma approach, significant genes are
identified by examining the p-values associated with differences in gene-specific
coefficients between different states (after a Bonferroni–Holm correction for multiple testing). We tested for both significant circadian genes (C1 category), as well
as genes that showed significant differences between states but not a circadian pattern, such as the C2 and C3 treatment categories outlined in Section 3.3. When
using limma to examine the entire set of genes for any significant differences
from the null hypothesis, we found 79.9% of genes were categorized in the null
category, which is larger than the null proportion found by either our method or
EBarrays. We also found that among the nonnull genes found by limma, only a
very small number (twelve genes) were categorized as something other than circadian, which is a much smaller than the number of nonnull and noncircadian genes
found by our method (given in Table 1). It appears that the simple analysis by
limma does not have the resolution necessary to detect genes that show noncircadian differential expression.
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4.2. Evaluation of model characteristics. A central assumption of our approach is the use of a Gamma distribution to model our gene expression
observations in each state. Newton et al. (2004) discuss diagnostics to appraise
the reasonableness of this Gamma assumption by examining the data for constant
coefficient of variation. If the assumption of constant coefficient of variation is
tenable, then genes ranked by their coefficient of variation should not share any
relationship with genes ranked by either their mean or standard deviation. In Figure 3 we plot genes ranked by coefficient of variation against genes ranked by
means, as well as genes ranked by standard deviations. We see from Figure 3 that
there is no substantial relationship between the coefficient of variation and the
mean or standard deviation, though there is some nonuniformity in the extremes.
However, it is worth noting that only a subset of the 22,283 genes in our dataset is
depicted in Figure 3. There is a substantial set of remaining genes that have very
low expression values, and correspondingly low variance of those expression values. The low variance of these additional genes would skew the appearance of the
diagnostic plots presented in Figure 3 if they were included. However, these addi-

F IG . 3. (a) Rank of genes by coefficient of variation against rank of genes by mean. (b) Rank of
genes by coefficient of variation against rank of genes by standard deviation.
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tional genes are not of primary interest since their low expression values put them
into the null hypotheses category. The main worry is that the presence of these low
expression genes will affect the ability of our model to detect nonnull hypotheses.
To investigate this possibility, we designed a small simulation study where realistic
synthetic data was generated that contained both null and nonnull genes, as well as
many null genes that have low-variance low-expression values. In these simulated
experiments, our approach was still able to detect the true nonnull genes despite
the presence of a substantial number of low-variance, low-expression null genes.
In addition to using simulated data to investigate our gamma assumption, we
also designed an extensive simulation study to evaluate the general performance
of our approach in carefully controlled situations. Specifically, we set global parameter values of α0 = 5, μ = 9 and α1 = α2 = α3 = α4 = 25 which approximate the
characteristics of our sleep apnea dataset (as seen in Figure 1). With these realistic
global parameter values, we then consider two data situations: datasets containing
100 genes each versus datasets containing 200 genes each. Each of these datasets
contained a mixture of approximately 75% null genes and 25% nonnull genes.
Note that these simulated datasets are much smaller than our sleep apnea study,
which gives us the chance to examine the operating characteristics of our model in
limited data situations. We implemented our model on one hundred datasets generated from each of these two data situations, and the results are shown in Table 3.
We see from the results in Table 3 that our model achieves accurate estimates
for the global parameters (α1 , α2 , α3 , α4 ) even in these limited data situations.
More problematic is the global parameter α0 , which only has 82% coverage in the
smaller (N = 100) datasets. The coverage improves for α0 in the larger (N = 200)
datasets, though even larger datasets seem to be needed to achieve proper coverage
TABLE 3
Parameter estimates for synthetic data generated under two conditions: N = 100 genes vs. N = 200
genes. For each global parameter, we give the mean across simulated datasets as well as the
coverage of the 95% posterior intervals. We also give the mean ± standard deviation
(across datasets) for the proportion of inferred nonnull genes
Global
parameter

N = 100 genes

N = 200 genes

True
value

Mean

95% coverage

Mean

95% coverage

α0
μ0
α1
α2
α3
α4

5
9
25
25
25
25

6.68
9.04
25.01
24.93
25.20
24.99

82
96
97
96
100
95

5.25
9.01
25.03
25.14
24.98
25.07

86
98
98
97
98
97

Proportion of
nonnull genes

0.25

0.231 ± 0.041

0.233 ± 0.033
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for this parameter. Also, even in these small datasets, our model classifies close to
the correct number of nonnull genes, and the small amount of error is in the conservative direction of a decreased number of nonnull classifications. Overall, these
simulation results are encouraging in terms of our model’s ability to achieve reasonable inference even in limited data situations, which bodes well for our sleep
apnea application where the available data is much more extensive.
4.3. Effect of outlier patients. Two of the thirteen patients in our study were
flagged by researchers at the University of Iceland as having phenotypic differences from the other eleven patients. These two patients (labeled here as patient X
and patient Y) are potential outliers that could have a dramatic effect on our model
inference. To address this possibility, we also fit our hierarchical Bayesian model
on datasets that had either (or both) of these patients removed. These alternative
analyses are listed in Table 4 along with our original model fit from Section 3
labeled as “Analysis A.”
Similar to our analysis of the original dataset from Section 3, we first examine
the estimated marginal posterior probabilities φ from each analysis. The estimated
posterior means of the marginal probability φk for each hypothesis k for all four
analyses (A–D) are given in Figure 4. We can see that the four analyses share the
same characteristics: the estimated φ are sparsely distributed, with the vast majority of mass concentrated at hypotheses 0 (null), 10 and 13. However, as seen
in Section 3.2, there is additional information at the level of the inferred hypotheses for individual genes, and so we also compared our four analyses in terms of
differences in the inferred gene-specific hypotheses.
For each alternative analysis (B, C and D), we calculated the number of discrepancies with analysis A, which we define as any genes that have a different inferred
hypothesis compared to the original analysis. The number of discrepancies for
each alternative analysis are given in Table 4, along with the number of genes with
nonnull inferred hypotheses for each analysis. The first observation is the relatively
small number of discrepancies between the methods, compared to the total number of genes in our dataset. In fact, 20,658 out of 22,283 genes (93%) showed no
TABLE 4
Discrepancies between different analyses
Analysis
label

Analysis
description

A
B
C
D

Original dataset with all 13 patients
Patient X excluded from dataset
Patient Y excluded from dataset
Both patient X and patient Y

Discrepancies
with analysis A

Number of
nonnull genes

0
774
887
596

4083
3437
4521
3642
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F IG . 4. Posterior mean of φk for the five hypotheses with the largest values of φk from all four
analyses (A–D).

discrepancy across any of the three alternative analyses. Looking at pairwise differences, removing patient X reduces the number of genes with inferred nonnull
hypotheses (from 4083 down to 3437) relative to our original analysis, whereas removing patient Y increases the number of genes with inferred nonnull hypotheses
(from 4083 up to 4521). The removal of both patients seems to balance these two
effects, which leads to the least number of discrepancies (596) when compared to
our original analysis. These results seem to suggest that our original analysis with
all patients included achieves a compromise between the more extreme results
from the alternative analyses with either patient X or patient Y excluded.
4.4. Applying the model to clusters of individuals. In our sleep apnea study,
expression levels are measured for the same 13 individuals in each state, and it is
likely that there will be correlation between individuals that could influence our
inference. We will examine the consequences of this possibility by first grouping
individuals that have correlated gene expression patterns across states. We calculated the correlation of gene expression patterns between each pair of individuals
and used these correlations as a distance metric for clustering (distance = 1− correlation). We then constructed a hierarchical clustering tree based on this distance
metric, shown in Figure 5, to group our individuals into two clusters. From Figure 5, it is clear that the most reasonable partitioning of our individuals into two
groups involves the three patients 3, 6 and 10 in one cluster, and the remaining 10
patients in the other cluster. We then fit our full Bayesian hypothesis testing model
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Clustering tree of patients based on gene expression correlation.

separately within each cluster, while allowing for different fitted model parameters
and inferred hypotheses for each gene within each cluster. Finally, we examined
the inferred hypotheses in each cluster for discrepancies between clusters as well
as discrepances with our original analysis. Interestingly, we found no discrepancies between the two clusters of individuals: every gene had the same inferred
hypothesis in the cluster 1 and cluster 2 datasets. However, we did find discrepancies between the clustered analysis and our original unclustered analysis: 2365
out of 22,285 genes (11%) had a different inferred hypothesis. Almost all of these
discrepancies (2363 out of 2365) are genes that were inferred to be nonnull in our
original unclustered analysis but now are inferred to be in the null group in our
clustered analysis. In fact, the only nonnull hypotheses that contained genes in our
clustered analysis were hypotheses 10 and 13 (circadian genes not affected by the
sleep apnea treatment). One explanation for these results is that splitting the dataset
into two clusters leads to a reduced sample size within each cluster and thus makes
nonnull hypotheses more difficult to infer from the data. A possible extension of
our approach would be to allow the clustering of individuals to vary instead of only
examining the particular clusters we used above. However, we believe that we are
taking a conservative approach since the clusters used in our analysis were chosen
in order to create the most dramatic difference between clusters.
4.5. Empirical evaluation of effect sizes. One concern when implementing
a model with a large space of hypotheses on data with a relatively small number of individuals (n = 13) is that inference will not be sensitive enough to detect
genes with small effect sizes. We explore this issue by examining the observed
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effect sizes for genes that were inferred to have significant differences (nonnull
hypotheses) by our analysis. Specifically, we examine particular hypotheses of two
different types:
1. Hypothesis 10 (μ1 = μ3 < μ2 = μ4 ) which is one of the popular circadian
hypotheses. Hypothesis 10 was inferred for 2433 genes by our analysis.
2. Hypothesis 3 (μ3 < μ1 = μ2 = μ4 ) which is a hypothesis for significant difference in a single state. Hypothesis 3 was inferred for only 5 genes by our
analysis.
Hypothesis 10 was chosen as the representative of the popular nonnull hypotheses
in our analysis, whereas hypothesis 3 was chosen as the representative of hypotheses with very small (but nonzero) numbers of inferred genes. For each of these two
hypotheses, we examined the distribution of “estimated effect sizes” for the set of
genes inferred to have that hypothesis. The key question is: how small of an effect
size can be detected by our analysis?
We can get an upper bound on the effect size needed for hypothesis 10 by looking at the minimum estimated effect size among the genes g inferred into the hypothesis 10 group. For each gene g inferred to have hypothesis 10, the estimated
effect size is
24

Yg =

13

Xg − Xg

,

sg

24

where X g is the mean of the expression levels Xgij over all individuals j within
13
states 2 and 4, whereas X g is the mean of the expression levels Xgij over all
individuals j within states 1 and 3. The effect sizes are scaled by sg , the pooled
standard deviation of the expression levels for gene g over the two groups (states 2
and 4 vs. states 1 and 3) and all individuals [Flury and Riedwyl (1986)]. The minimum estimated effect size Yg found for genes inferred to have hypothesis 10 was
24
13
0.11, which means that our analysis can detect circadian effect sizes X g − X g
that are as small as only 0.11 of the standard deviation sg . Part of the reason for
this high sensitivity is the somewhat large marginal probability φ 10 = 0.12 that is
estimated by our analysis for hypothesis 10.
We also get an upper bound on the effect size needed for the less popular hypothesis 3 by looking at the estimated effect size
124

Yg =

3

Xg − Xg
sg
124

for genes g inferred to have hypothesis 3. X g

is the mean of the expression lev3

els Xgij over all individuals j within states 1, 2 and 4, whereas X g is the mean of
the expression levels Xgij over all individuals j within just state 3, and again the
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effect sizes are scaled by sg , the pooled standard deviation of the expression levels
for gene g over the two groups (states 1, 2 and 4 vs. state 3) and all individuals.
Among the five genes inferred to have hypothesis 3, the minimum estimated effect
size Yg was 0.32, which suggests that our analysis requires larger effect sizes (0.32
of the standard deviation sg ) to detect a significant noncircadian effect. Again, part
of the reason for this reduced sensitivity is the much smaller marginal probability
φ 3 = 0.001 of hypothesis 3 that is estimated from our model fit. However, despite this reduced sensitivity, we still observe genes inferred into these nonnull and
noncircadian categories within our analysis, which suggests that the effect sizes
needed for detection of nonnull effects are not unrealistic for the current study. Indeed, we observe even larger minimum estimated effect sizes among other nonnull
hypotheses that still contained inferred genes. The most extreme case is hypothesis 6, which has three inferred genes despite having a large minimum estimated
effect size (0.67 of the standard deviation sg ) and a small marginal probability
φ 6 = 0.001.
5. Summary and discussion. Motivated by a large study of sleep apnea treatment, we have presented methodology for a relatively under-explored hypothesis testing context: testing not only many units but also many hypotheses within
each unit. This situation is prevalent in many biological investigations, where the
units are usually genes and where the experimental design dictates that expression data for an entire genome is to be measured across several states. Our proposed Bayesian hierarchical model is a natural framework for testing for differences across states while controlling for that large number of comparisons that
need to be made within the experimental design. In addition to comparison with
previous methods, we have also provided an extensive exploration and validation
of our modeling assumptions. As shown in Section 3.3, our procedure also easily
accommodates the collapsing of certain hypotheses into larger groupings that may
also be of interest. Genes inferred into the treatment categories of hypotheses are
candidates for future studies into more refined treatments of sleep apnea, as well
as general studies into the genetic basis of sleep behavior.
Many analyses of expression data across several conditions or states focus on
the grouping of genes into clusters of similar expression patterns [e.g., Medvedovic
and Sivaganesan (2002), Ma et al. (2006)]. The focus of our procedure differs substantially from a clustering-based analysis, since our interest lies in using the experimental design to identify genes that fulfill specific hypotheses. Interpretation
of the results from a clustering analysis is more difficult since one must assign
biological hypotheses to each gene cluster post hoc. However, although our model
and implementation can be easily generalized to an increasing number of conditions, the interpretation of our own rapidly increasing space of possible hypotheses becomes more difficult. Thus, as the number of states grows to be quite large,
clustering-based approaches become a more attractive alternative. Our methodology is most appropriate for the frequent intermediary situation where one wants
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to simultaneously test many genes × many hypotheses within each gene across a
modest number of states.
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SUPPLEMENTARY MATERIAL
Gibbs sampling implementation and full list of hypotheses (DOI: 10.1214/09AOAS241SUPP; .pdf). We provide details of our Markov chain Monte Carlo
implementation, which is based on a Gibbs sampling algorithm [Geman and
Geman (1984)]. We also give a full enumeration of the hypotheses considered
in Section 2.1.
REFERENCES
A LIZADEH , A., E ISEN , M., DAVIS , R., M A , C., L OSSOS , I., ROSENWALD , A., B OLDRICK , J.,
S ABET, H., T RAN , T., Y U , X., P OWELL , J., YANG , L., M ARTI , G., M OORE , T., H UDSON ,
J., L U , L., L EWIS , D., T IBSHIRANI , R., S HERLOCK , G., C HAN , W., G REINER , T., W EISEN BURGER , D., A RMITAGE , J., WARNKE , R., L EVY, R., W ILSON , W., G REVER , M., B YRD ,
J., B OTSTEIN , D., B ROWN , P. and S TAUDT, L. (2000). Distinct types of diffuse large b-cell
lymphoma identified by gene expression profiling. Nature 403 503–511.
B ICKEL , P. and D OKSUM , K. (2007). Mathematical Statistics: Basic Ideas and Selected Topics 1,
2nd ed. Prentice Hall, Upper Saddle River, NJ.
D EMPSTER , A., L AIRD , N. and RUBIN , D. (1977). Maximum likelihood from incomplete data via
the em algorithm. J. Roy. Statist. Soc. Ser. B 39 1–38. MR0501537
D UDOIT, S., G ENTLEMAN , R. C. and Q UACKENBUSH , J. (2003). Open source software for the
analysis of microarray data. BioTechniques 34 S45–S51.
F LURY, B. K. and R IEDWYL , H. (1986). Standard distance in univariate and multivariate analysis.
Amer. Statist. 40 214–215. MR0857143
G EMAN , S. and G EMAN , D. (1984). Stochastic relaxation, Gibbs distributions, and the Bayesian
restoration of images. IEEE Transaction on Pattern Analysis and Machine Intelligence 6 721–
741.
G OTTARDO , R., R AFTERY, A. E., Y EUNG , K. Y. and B UMGARNER , R. E. (2006). Bayesian robust
inference for differential gene expression in microarrays with multiple samples. Biometrics 62
10–18. MR2226551
I RIZARRY, R. A., H OBBS , B., C OLLIN , F., B EAZER -BARCLAY, Y. D., A NTONELLIS , K. J.,
S CHERF, U. and S PEED , T. P. (2006). Exploration, normalization, and summaries of high density
oligonucleotide array probe level data. Biostatistics 4 249–264.
J ENSEN , S. T., E RKAN , I., A RNADOTTIR , E. S. and S MALL , D. S. (2009). Supplement to
“Bayesian testing of many hypothesis × many genes: A study of sleep apnea.” DOI: 10.1214/09AOAS241SUPP.
K ENDZIORSKI , C. M., N EWTON , M. A., L AN , H. and G OULD , M. N. (2003). On parametric
empirical Bayes methods for comparing multiple groups using replicated gene expression pr.
Stat. Med. 22 3899–3914.
M A , P., C ASTILLO -DAVIS , C., Z HONG , W. and L IU , J. S. (2006). A data-driven clustering method
for time course gene expression data. Nucleic Acids Research 34 1261–1269.

BAYESIAN HYPOTHESIS TESTING

1101

M EDVEDOVIC , M. and S IVAGANESAN , S. (2002). Bayesian infinite mixture models based clustering of gene expression profiles. Bioinformatics 18 1194–1206.
N EWTON , M., K ENDZIORSKI , C. M., R ICHMOND , C. S., B LATTNER , F. R. and T SUI , K. W.
(2001). On differential variability of expression ratios: Improving statistical inference about gene
expression changes from microarray data. J. Comput. Biol. 8 37–52.
N EWTON , M., N OUEIRY, A., S ARKAR , D. and A HLQUIST, P. (2004). Detecting differential gene
expression with a semiparametric hierarchical mixture method. Biostatistics 5 155–176.
PACK , A. I. (2006). Advances in sleep-disordered breathing. Am. J. Respir. Crit. Care. Med. 173
7–15.
S EGAL , E., S HAPIRA , M., R EGEV, A., P E ’ ER , D., B OTSTEIN , D., KOLLER , D. and F RIEDMAN ,
N. (2003). Module networks: Identifying regulatory modules and their condition-specific regulators from gene expression data. Nature Genetics 34 166–176.
S MYTH , G. (2004). Linear models and empirical bayes methods for assessing differential expression
in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3 3. MR2101454
S TOREY, J. D. and T IBSHIRANI , R. (2003). Statistical significance for genomewide studies. Proc.
Natl. Acad. Sci. 100 9440–9445. MR1994856
W U , Z., I RIZARRY, R. A., G ENTLEMAN , R., M URILLO , F. M. and S PENCER , F. (2004). A model
based background adjustment for oligonucleotide expression arrays. Technical Report Paper 1,
Dept. Biostatistics, Johns Hopkins Univ.
Y UAN , M. and K ENDZIORSKI , C. (2006). A unified approach for simultaneous gene clustering and
differential expression identification. Biometrics 62 1089–1098. MR2297680
S. T. J ENSEN
I. E RKAN
D. S. S MALL
D EPARTMENT OF S TATISTICS
T HE W HARTON S CHOOL
U NIVERSITY OF P ENNSYLVANIA
P HILADELPHIA , P ENNSYLVANIA 19104
USA
E- MAIL : stjensen@wharton.upenn.edu
erkan@wharton.upenn.edu
dsmall@wharton.upenn.edu

E. S. A RNARDOTTIR
D EPARTMENT OF R ESPIRATORY
M EDICINE AND S LEEP
L ANDSPITALI U NIVERSITY H OSPITAL
AND

T HE FACULTY OF M EDICINE
U NIVERSITY OF I CELAND
108 R EYKJAVIK
I CELAND
E- MAIL : ernasif@landspitali.is

